AstraZeneca said Monday that its COVID-19 vaccine can be 90% effective, giving the global war against the global pandemic a new weapon, cheaper to manufacture, easier to distribute, and faster in size. Then its competitors.
The British pharma said it will receive up to 200 million doses by the end of 2020, nearly four times its US rival Pfizer.
The vaccine costs for governments a few dollars per injection, which is a fraction of the price of injections from Pfizer and Moderna, which use less traditional technology.
In poor countries, where the logistics of competing vaccine distribution poses a greater challenge, the impact of a cheaper and easier alternative could be more pronounced. Zahid Maleque, Bangladeshi Minister of Health, who is purchasing 30 million doses of AstraZeneca vaccine made in India, described the results as "very good news".
23 November 2020